
Exazyme helps biotech teams design and optimize proteins faster by reducing experimental cycles while improving properties like stability, activity, and specificity. The company provides an AI/ML-driven protein design platform that combines bioinformatics, proprietary models, and prior biological knowledge to explore large sequence spaces with fewer experiments. Offered as an all-in-one application with on-site deployment and strong data privacy, the platform targets biotech and pharmaceutical customers seeking protein engineering at scale. Exazyme integrates computational design, experimental planning, and model-guided optimization to deliver measurable outcomes such as improved carbon fixation and reduced client energy use.

Exazyme helps biotech teams design and optimize proteins faster by reducing experimental cycles while improving properties like stability, activity, and specificity. The company provides an AI/ML-driven protein design platform that combines bioinformatics, proprietary models, and prior biological knowledge to explore large sequence spaces with fewer experiments. Offered as an all-in-one application with on-site deployment and strong data privacy, the platform targets biotech and pharmaceutical customers seeking protein engineering at scale. Exazyme integrates computational design, experimental planning, and model-guided optimization to deliver measurable outcomes such as improved carbon fixation and reduced client energy use.
What they do: AI-driven protein design platform to accelerate protein design and optimization
Headquarters: Berlin, Germany
Stage / funding: Seed (last reported May 2023)
Target customers: Pharmaceutical, industrial, and green-biotech organizations (B2B)
Founded: 2022
Protein design and optimization for biotech applications
2022
Biotechnology
Seed round reported May 15, 2023; investors reported to have participated include AIX Ventures and Atlantic Labs.
Pre-seed round reported November 2022; IBB Ventures listed as an early-round participant.
“AIX Ventures, Atlantic Labs and IBB Ventures are reported investors”